Transcranial magnetic stimulation and transcranial direct current stimulation appear to be safe neuromodulatory techniques useful in the treatment of anxiety disorders and other neuropsychiatric disorders

Aline Iannone1, Antonio Pedro de Mello Cruz1, Joaquim Pereira Brasil-Neto2, Raphael Boechat-Barros3

ABSTRACT
Transcranial magnetic stimulation (TMS) has recently been investigated as a possible adjuvant treatment for many neuropsychiatric disorders, and has already been approved for the treatment of drug-resistant depression in the United States and in Brazil, among other countries. Although its use in other neuropsychiatric disorders is still largely experimental, many physicians have been using it as an off-label add-on therapy for various disorders. More recently, another technique, transcranial direct current stimulation (tDCS), has also become available as a much cheaper and portable alternative to TMS, although its mechanisms of action are different from those of TMS. The use of off-label therapeutic TMS or tDCS tends to occur in the setting of diseases that are notoriously resistant to other treatment modalities. Here we discuss the case of anxiety disorders, namely panic and post-traumatic stress disorders, highlighting the uncertainties and potential problems and benefits of the clinical use of these neuromodulatory techniques at the current stage of knowledge.

Keywords: transcranial direct current stimulation; anxiety; panic disorder.

RESUMO
A estimulação magnética transcraniana (TMS) foi recentemente proposta como um possível tratamento adjuvante para muitos distúrbios neuropsiquiátricos, e já foi aprovada para o tratamento de depressão fármaco-resistente nos Estados Unidos e no Brasil, entre outros países. Apesar do fato de que seu uso em outros transtornos neuropsiquiátricos ainda é em grande parte experimental, muitos médicos têm utilizado essas técnicas como uma terapia off-label em várias doenças. Mais recentemente, uma outra técnica, a estimulação transcraniana por corrente contínua (ETCC), tornou-se também disponível como uma alternativa muito mais barata e portátil do que a TMS, embora os seus mecanismos de ação sejam diferentes daquela da TMS. O uso off-label de TMS ou ETCC tende a ocorrer no caso de doenças que são notoriamente resistentes a outras modalidades terapêuticas. Aqui nós discutimos o caso dos transtornos de ansiedade, ou seja, transtorno do pânico e estresse pós-traumático, destacando as incertezas, benefícios e problemas potenciais inerentes ao uso clínico dessas técnicas neuromoduladoras no atual estágio do conhecimento.

Palavras-chave: estimulação transcraniana por corrente contínua; ansiedade; transtorno de pânico.
Parkinson’s, and epilepsy. In the last two decades, research on using these tools to treat conditions such as depression, mania, obsessive-compulsive disorder and post-traumatic stress disorder began to appear.

The use of electric currents for treating psychiatric disorders began in the 18th century with the development of the voltaic pile. However, it was only in the 1960s and 1970s that the noninvasive method of cerebral stimulation known as brain polarization, similar to modern tDCS, was able to provide improvements in mood and alertness in healthy volunteers, in addition to treating depression. Later, this method was abandoned, possibly due to the advance of psychopharmacology and the social stigma of electroconvulsive therapy that hindered the development and emergence of new noninvasive forms of cerebral stimulation.

Despite the controversies involving such an early noninvasive method of cerebral stimulation, tDCS began to be used again as a putative neuromodulatory tool in the present century, notably with the studies of Priori in Italy, and Nitsche and Paulus in Germany. Both studies were able to demonstrate that the transcranial induction of a low-intensity direct current, through electrodes placed on the head, increased (anodal stimulation) or decreased (cathodal stimulation) cortical excitability during the period of stimulation, suggesting that tDCS probably produced its effects through changes in the resting membrane potential, thus modifying the threshold for firing of action potentials, or even through synaptic mechanisms.

As a neuromodulatory technique, its physical and physiological principles require less complex equipment than TMS, with only two electrodes being necessary: one cathode and one anode, which, arranged in different positions, create a flow of low-intensity (1 or 2 mA) direct electric current that covers a specific region of the cerebral cortex, modulating it in accordance to the polarity. The electric current, in turn, flows from one electrode to the other through the scalp and the cortex. By comparison, while TMS can generate strong currents capable of depolarizing the neuron until it reaches the threshold for firing action potentials, tDCS changes cortical activity through weak electric currents, producing changes in the resting membrane potential, and consequently in brain activity.

One fact that stands out in tDCS is the duration of its physiological effects. The technique is able to decrease or increase cortical excitability for hours after stimulation, probably by inducing long-term depression or long-term potentiation on the treated neurons and synapses. Due to these long-term changes in cortical excitability, it is commonly applied daily, for 20 to 30 minutes, ensuring efficacy and safety. Taking into account its prolonged effects upon cortical excitability, low intensity of the currents used to modulate brain activity, as well as the fact that it also allows sham stimulation in experimental protocols, tDCS has been widely accepted not only as an off-label treatment but also as a research tool, instead of high-cost equipment such as magnetic stimulators. Furthermore, the technique appears to be quite safe, and there is no reason to-date to suspect tDCS to be detrimental to health, since it presents a low rate of side effects when used in accordance with the standard procedures recommended by recent clinical studies for the treatment of psychiatric disorders. The only side effects associated with tDCS have been redness of the skin or mild superficial electrolytic burns. However, due to the still short follow-up time of treated subjects, longer-term side effects, if any, are unknown at this time.

APPLICATIONS OF TMS AND TDCS IN PSYCHIATRY

While in the past it was necessary to surgically manipulate the brain in order to modulate its activity in a pharmacological way, noninvasive stimulation provides something new: through TMS and tDCS, it is possible to adjust cerebral activity and apparently even mental processes, with less risk than is inherent in manipulation through neurostimulator implant surgery or by using drugs.

Due to the increasing incidence of mood disorders and anxiety in the global population, researchers have sought increasingly effective, safe and noninvasive investigative and therapeutic techniques, with a lower incidence of adverse effects, for these disorders. According to the World Health Organization, depression and anxiety are among the most prevalent diseases in society, as per the tenth edition of the International Classification of Diseases (ICD-10), and are considered “common mental disorders” due to their high level of comorbidity and because they have similar therapeutic approaches. Research in the clinical field is needed in order to discover more effective and less invasive new treatments, given that not all patients respond to psychopharmacological or psychotherapeutic interventions.

NONINVASIVE TRANSCRANIAL STIMULATION FOR MAJOR DEPRESSIVE DISORDER

Transcranial magnetic stimulation has received FDA approval for the treatment of major depressive disorder. One notable fact is that a third of major depressive disorder patients are treatment-resistant, defined by the lack of adequate response of the symptoms after two or three antidepressant treatments. Due to the high prevalence of resistance to treatment and failed antidepressant response, the National Institute of Mental Health developed the Sequenced Treatment Alternatives to Relieve Depression Trial, a systematic protocol for treating depression. According to the latter protocol, cumulative response and remission rates after two unsuccessful antidepressant treatments are 73% and 47% respectively. Based on these data,
numerous repetitive TMS (rTMS) studies have been performed on the treatment of major depressive disorder and have shown positive results, suggesting that low-frequency stimulation (1Hz) of the right dorsolateral prefrontal cortex, or high frequency over the left dorsolateral prefrontal cortex, both have antidepressant effects²⁴.

Double-blind studies have been developed using anodal tDCS on the left dorsolateral prefrontal cortex, with low intensities between 1 and 2mA, over 10 days or more, and have shown positive results in reducing depressive symptoms²⁵,²⁶. In the study by Fregni et al.²⁵, the results indicated a 69% improvement in symptoms of depression after just five sessions of tDCS, after 1.5 weeks, compared to a 30% improvement in the control group, measured on the Hamilton Depression Rating Scale. The same results were found by Boggio et al.²⁶, with an improvement of 40.5% in the group that received tDCS, in comparison to 10.4% of the control group, after two weeks of treatment. Taking into account these promising results of tDCS as an antidepressant treatment, replication of these studies in the future is suggested.

**EFFECTS OF TRANSCRANIAL STIMULATION UPON ANXIETY DISORDERS**

In addition to depression, the effects of transcranial stimulation on anxiety disorders and related disorders have also been investigated. However, before discussing some of these studies, it should be noted that, based on the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V, 2014), published by the American Psychiatric Association, some disorders such as anxiety disorders, classically recognized by the international community, have been registered separately in this latest edition of the DSM, in their own chapters, with separate nosologies. Among these are obsessive-compulsive disorder (OCD), post-traumatic stress disorders (PTSD) and acute stress. This new and controversial classification has been the target of criticism, but it is not the purpose of this review to analyze its pros and cons. Thus, for the description and analysis of some of the main studies investigating the effects of transcranial stimulation on OCD and PTSD, before and after the publication of the DSM-V, a purely descriptive analysis of their clinical results is adopted, without considering whether or not they are anxiety disorders according to this version of the DSM.

**NEUROMODULATION AND OBSESSIVE-COMPULSIVE DISORDER**

Obsessive-compulsive disorder is characterized by the presence of obsessions and/or compulsions, where obsessions are thoughts, impulses or recurrent and persistent images that are intrusive and unwanted experiences, while compulsions are repetitive behaviors or mental acts that an individual feels compelled to perform in response to an obsession or according to a set of rules that must be rigidly applied. Because it is a chronic disease characterized by obsessions and compulsions, OCD causes discomfort to the patient and his/her family²⁷ and was ranked as the fourth most common psychiatric disorder, affecting approximately 1–3% of the global population²⁸. It is also known that the disease is associated with dysfunction in the frontostriatal circuit, including the dorsolateral prefrontal cortex, orbitofrontal cortex, and medial prefrontal cortex, as well as the supplementary motor area, supplemental gyrus, anterior cingulate gyrus and basal ganglia²⁹. An interesting fact is that only 40-60% of patients respond to pharmacological treatment and cognitive behavioral therapy³⁰, justifying the use of new techniques in order to reduce resistance to treatment in these patients. Further research is still needed to provide a better understanding of the neural circuits involved in this disorder, since aspects of its etiology and pathophysiology remain unknown. Recent studies with rTMS emphasize that inhibitory application at a low frequency (1 Hz) on the supplementary motor area improves symptoms and increases the motor threshold³¹ and intracortical inhibition measured by the matched magnetic pulses technique³², the latter considered to be dependent on GABAergic mechanisms. These results corroborate the findings of Gomes et al.³³ who, in a recent randomized, double-blind study of OCD patients, showed that those who received rTMS on the supplementary motor area over two weeks had 35% improvement in OCD symptoms (Y-BOCS scale). Also in relation to symptoms of anxiety, there was a reduction in symptoms of 19.6% in the tDCS group compared to 9.5% in the group undergoing control stimulation, according to the anxiety scale (Hamilton Rating Scale for Anxiety - HRAS-14) after two weeks of stimulation. As to the symptoms of depression, they found no significant difference between tDCS and control groups on the Hamilton Scale for Depression (HRSD-24). In recent literature reviews, Berlim et al.³⁴ and Senço et al.³⁵ also observed that response rates among patients who received low-frequency rTMS on the orbitofrontal cortex or supplementary motor area vary between 35% and 13%, making these areas promising targets for reducing the symptoms of OCD, but studies are still incipient, as pointed out by some authors³⁶.

**NEUROMODULATION AND POST-TRAUMATIC STRESS DISORDER**

In addition to OCD, a few studies have also investigated the effects of transcranial stimulation on PTSD. This is a psychiatric condition that occurs in people who have
witnessed events involving active threat of death or serious injury, or a threat to the physical safety of themselves or others and is characterized by three symptom clusters: re-experience, avoidance and hyperarousal, resulting in social or occupational dysfunction. The symptoms must be present for at least a month, and may last for years. It is also a condition in which exposure to a risk against life results in a set of intrusive memories, where the individual experiences events associated with stress. Epidemiological studies estimate that 7.8% of the US population suffer from PTSD at some point in their lives, suggesting a psychosocial and economic loss exceeding US$ 3 billion in lost productivity to the US every year.

Pharmacological studies have shown that reduced glutamatergic neurotransmission, by AMPA receptor blockage, results in anxiolytic effects. In PTSD patients, this effect results in reduced flashbacks and nightmares, typical symptoms of the disorder. Regarding the hypothalamic-pituitary-adrenal axis, hypocortisolemia is different from other anxiety disorders. It is not exactly known why the reduction occurs, but it has been found that when cortisol levels are lower in PTSD, the severity of symptoms is greater. However, although many drugs have demonstrated therapeutic benefit in humans with PTSD and many of these drugs have been shown to be capable of preventing anxious behavior and cognitive impairment in rats with stress, not all patients respond to pharmacological treatment options for PTSD. For this reason, non-pharmacological treatments and noninvasive methods such as rTMS and tDCS have been tried.

A few studies have shown that administration of low-frequency rTMS on the right dorsolateral prefrontal cortex is beneficial for improving the symptoms of PTSD, by decreasing cortical excitability. Garcia-Toro et al. demonstrated that refractory PTSD patients showed an improvement of clinical symptoms after 10 sessions of low-frequency rTMS (1 Hz) applied to the right dorsolateral prefrontal cortex. In a complementary manner, Osuch et al. demonstrated that patients who had 20 sessions of low-frequency rTMS (1 Hz) on the right dorsolateral prefrontal cortex and PTSD exposure therapy showed a reduction in the symptomatic and psychophysiological effects of PTSD, as assessed by the Hamilton Depression Rating Scale, the Impact of Events Scale and the Clinical Administered PTSD Scale. Curiously, a group of researchers has been conducting experiments using high-frequency rTMS (10 Hz) instead of low frequency rTMS in patients with PTSD, and has also reported positive results. Such experiments, however, still need to be replicated by other researchers, on the basis of variable conflicting results.

**Correlation with neuroimaging studies**

Neuroimaging studies on rTMS and PTSD have shown increased oxygenation in the right prefrontal cortex when participants are exposed to experiences that remind them of the traumatic experiences, suggesting that overactivity on the right side in PTSD is associated with the role of the right hemisphere in anxiety and other adverse emotional experiences. Thus, low-frequency rTMS (1 Hz) might decrease activity in the cortical areas of the right hemisphere, which in turn might improve the abnormalities and reduce cerebral functional asymmetries associated with PTSD. Still, hyperactivation of the amygdala and the rostral region of the cingulate cortex is observed in these patients, and the higher the activation of these regions, the greater the severity of the symptoms of PTSD.

These findings therefore suggest that rTMS on the right dorsolateral prefrontal cortex seems to be well suited to become an effective tool in the treatment of PTSD; moreover, there is evidence that rTMS produces anxiolytic action in humans. Berlim et al. reviewed several randomized controlled studies conducted between 1995 and 2013 and found that studies on PTSD patients in which rTMS was applied on the right dorsolateral prefrontal cortex pointed to significant differences from patients undergoing sham rTMS. In addition, there were differences in the symptoms of anxiety and depression among PTSD patients before and after rTMS. Additionally, Karsen et al. conducted a review of published reports including a total of 132 patients to evaluate the efficacy of rTMS in the treatment of PTSD. Based on the review, it was found that the variables most often studied were: a) treatment of the right or left cerebral hemisphere; b) stimulation frequency (0.3, 1, 5, 10 or 20 Hz); c) anatomical location; d) number of stimulation pulses; e) combination of rTMS with exposure. All studies stimulated pre-frontal regions.

**Neuromodulation for PTSD and the right-left dilemma**

Boggio et al. demonstrated that high-frequency rTMS (20Hz) of either the right or left cerebral hemisphere can be effective in reducing the symptoms of PTSD. In contrast, some authors have observed that low-frequency rTMS (1 Hz) on the right dorsolateral prefrontal cortex seems to be more effective. Again, however, Cohen et al., upon comparing low-frequency rTMS (1Hz) and high-frequency rTMS (10Hz) on the right dorsolateral prefrontal cortex, concluded that high-frequency rTMS showed greater improvement of PTSD symptoms compared to low-frequency rTMS (29.3 % and 10.4% respectively). Furthermore, Rosenberg et al. compared the effect of low-frequency and high-frequency rTMS (1 Hz and 5 Hz, respectively) and found low-frequency rTMS on the left dorsolateral prefrontal cortex to be efficient in reducing depressive symptoms, but not PTSD symptoms.

Although studies have demonstrated effects on cortical activation for both high-frequency and low-frequency stimulation, and treatment of both the right and left dorsolateral prefrontal cortices have been shown to reduce...
symptoms of PTSD, it is not yet understood how stimulation of the dorsolateral prefrontal cortex affects this neural circuitry. Regarding the rTMS mechanism of action in PTSD, it is known that: a) stimulating the right dorsolateral prefrontal cortex with a high frequency activates the hypothalamic-pituitary-adrenal axis, inhibiting excessive autonomic response and suppressing activity of the amygdala; b) stimulating the right dorsolateral prefrontal cortex with a low frequency inhibits the right hemisphere, reducing hyperactivity of the right prefrontal cortex in patients with PTSD. Thus, both low-frequency and high-frequency rTMS, when applied to the right side, are potentially well suited to reduce the symptoms of PTSD.

**Limitations of PTSD and PTSD-depression studies**

Regarding the limitations of PTSD studies, Karsen et al. suggest that, although there are studies in which both frequencies can contribute to a decrease in the symptoms of PTSD, one frequency may be better than the other, and further research is therefore needed in this area. Furthermore, the small number of subjects in these analyses limits any generalization of the findings, which increases the need for further studies with larger samples and improved stimulation parameters; moreover, the mechanism of action of rTMS in anxiety disorders needs to be further clarified, by combining TMS with neuroimaging.

In addition to treatment with rTMS, PTSD is also treated through exposure to objects and events that induce anxiety and memories of aversive episodes, but in a controlled environment so that patients know that they are not in danger. Finally, the frequent coexistence of anxiety and mood disorders justifies the concomitant study, for example, of panic disorder and major depressive disorder with rTMS. Many researchers have been interested in both psychiatric disorders, since they lead to a decrease in functionality, resulting in increased morbidity and suicide rates.

**NEUROMODULATION AND PANIC DISORDER**

Although less numerous, studies have also been published on the effects of transcranial stimulation in patients with PD. For example, low-frequency rTMS (1 Hz) on the right dorsolateral prefrontal cortex seems to lessen the symptoms of panic in these patients. There seems to be an activation asymmetry, so that, in PD patients, the right hemisphere appears to be more active than the left in the dorsolateral prefrontal cortex area.

**Right-sided low-frequency rTMS and PD**

To test the clinical effects of low-frequency rTMS (1 Hz) on the right dorsolateral prefrontal cortex of patients with PD and depression who are resistant or intolerant to medication, Zwanzger et al. observed that after two weeks of rTMS treatment there was significant improvement in symptoms of anxiety and depression, corroborating the findings of Mantovani et al. Later, Mantovani et al. demonstrated that, after four weeks of low-frequency rTMS stimulation of the right dorsolateral prefrontal cortex, patients who received real treatment fared better than those who received only sham stimulation. It can therefore be concluded that low-frequency rTMS on the right dorsolateral prefrontal cortex improves symptoms of major depression and anxiety disorders.

Low-frequency rTMS (1 Hz) on the right dorsolateral prefrontal cortex decreased symptoms of panic according to Li et al., although the difference was not significant between patients who received rTMS and sham rTMS, measured by the Panic Disorder Severity Scale.

**Left-sided high-frequency rTMS stimulation and PD**

In contrast, Pallanti and Bernardi concluded that high-frequency rTMS on the right dorsolateral prefrontal cortex reduced symptoms in anxiety disorders and had positive results in patients with PTSD and PD, while the case study by Sakkas et al. in which high-frequency rTMS (10-20 Hz) was administered to the left dorsolateral prefrontal cortex in a patient with PD who was resistant to pharmacological treatment, also showed an improvement in symptoms. These findings are in keeping with other studies that compared high-frequency rTMS over the left dorsolateral prefrontal cortex to the effects of antidepressants. Additionally, Dresler et al. demonstrated improvements in symptoms of patients diagnosed with PD as a result of three weeks of high-frequency rTMS over the left dorsolateral prefrontal cortex, confirming the study by Guiana et al., which found an improvement in the symptoms of anxiety on the Panic Disorder Severity Scale.

A limitation of the rTMS method in anxiety disorders is that its impact is on the cortical surface layers, and it is not possible to directly stimulate more distant cortical and subcortical areas that are relevant to the pathogenesis of anxiety disorders. Thus, further studies are recommended to determine the role of tDCS in the treatment of anxiety disorders, since it is a less focal stimulation and may influence deeper neuronal circuits.

In conclusion, both TMS and tDCS appear to be safe and useful neuromodulatory techniques with potential application in the treatment of anxiety disorders, as well as a number of other neuropsychiatric disorders. However, as is well illustrated by this review of anxiety disorders, larger clinical trials are needed if consensus is to be reached regarding indications, optimal treatment protocols and clinical relevance of these non-pharmacological interventions. Moreover, caution should be exercised to avoid abusive use of these powerful neuromodulatory techniques, due to the uncertainties about their exact mechanism of action and possible long-term side effects.
References


